A detailed history of Atria Wealth Solutions, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Atria Wealth Solutions, Inc. holds 6,494 shares of CRSP stock, worth $310,932. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,494
Previous 6,450 0.68%
Holding current value
$310,932
Previous $348,000 12.36%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$44.62 - $62.75 $1,963 - $2,761
44 Added 0.68%
6,494 $305,000
Q2 2024

Jul 22, 2024

SELL
$51.17 - $68.18 $66,469 - $88,565
-1,299 Reduced 16.76%
6,450 $348,000
Q1 2024

May 13, 2024

BUY
$60.67 - $89.12 $80,448 - $118,173
1,326 Added 20.64%
7,749 $528,000
Q4 2023

Feb 02, 2024

BUY
$38.62 - $72.18 $32,015 - $59,837
829 Added 14.82%
6,423 $402,000
Q2 2023

Aug 03, 2023

SELL
$43.47 - $67.77 $10,085 - $15,722
-232 Reduced 3.98%
5,594 $314,000
Q1 2023

Aug 22, 2023

BUY
$41.0 - $56.12 $196,841 - $269,432
4,801 Added 85.82%
10,395 $470,000
Q1 2023

Jun 14, 2023

SELL
$41.0 - $56.12 $187,329 - $256,412
-4,569 Reduced 43.95%
5,826 $263,000
Q1 2023

May 10, 2023

BUY
$41.0 - $56.12 $187,329 - $256,412
4,569 Added 78.42%
10,395 $470,000
Q4 2022

Aug 30, 2023

BUY
$39.19 - $65.67 $9,092 - $15,235
232 Added 4.15%
5,826 $236,000
Q4 2022

Feb 13, 2023

SELL
$39.19 - $65.67 $198,066 - $331,896
-5,054 Reduced 46.45%
5,826 $236,000
Q3 2022

Feb 13, 2023

BUY
$61.1 - $83.78 $109,491 - $150,133
1,792 Added 19.72%
10,880 $711,000
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $202,790 - $278,065
3,319 Added 57.53%
9,088 $589,000
Q2 2022

Aug 15, 2022

BUY
$43.23 - $73.83 $249,393 - $425,925
5,769 New
5,769 $351,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Atria Wealth Solutions, Inc. Portfolio

Follow Atria Wealth Solutions, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Wealth Solutions, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Atria Wealth Solutions, Inc. with notifications on news.